Tech Company Financing Transactions
eFFECTOR Therapeutics Funding Round
eFFECTOR Therapeutics secured a $40 million Series B funding round on 12/22/2015. Investors included Altitude Life Science Ventures, AbbVie Biotech Ventures and BioMed Ventures.
Transaction Overview
Company Name
Announced On
12/22/2015
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series B
Investors
Proceeds Purpose
The funds will support an open-label Phase 1/2 trial that will evaluate daily oral administration of eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, in patients with advanced solid tumors. The Series B proceeds will fund multiple expansion arms for eFT508 in solid tumors and lymphoma, as well as advancing the company's second program into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11180 Roselle St.
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Worland
Chief Financial Officer
Alana McNulty
VP - R & D
Siegfried Reich
Browse more venture capital transactions:
Prev: 12/21/2015: SpiderCloud Wireless venture capital transaction
Next: 12/22/2015: Smart Choice MRI venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs